SBI-0640756

Catalog No.S8181 Batch:S818101

Print

Technical Data

Formula

C23H14ClFN2O2
Molecular Weight 404.82 CAS No. 1821280-29-8
Solubility (25°C)* In vitro DMSO 80 mg/mL (197.61 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
4.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 80 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.66mg/ml Taking the 1 mL working solution as an example, add 50 μL of 13.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SBI-0640756(SBI-756) is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex. It can also suppress AKT and NF-κB signaling.
Targets
eIF4G1 [1]
In vitro

SBI-756 impaired the eIF4F complex assembly independently of mTOR and attenuated growth of BRAF-resistant and BRAF-independent melanomas.It also supresses AKT and NF-kB signaling. SBI-756 inhibits the growth of NRAS, BRAF, and NF1-mutant melanomas in vitro[1].
In vivo

SBI-756 delays the onset and reduces the incidence of Nras/Ink4a melanomas in vivo[1].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    Melanoma lines

  • Concentrations

    1, 2, 5 μmol/L

  • Incubation Time

    48 h

  • Method

    Melanoma lines are plated (triplicates 384-well plates; 1,500 cells per well) and cell viability is assessed 48 hours after treatment with indicated compounds. Growth inhibition is calculated as percentage of DMSO-treated controls and is plotted against the log drug concentration.

Selleck's SBI-0640756 has been cited by 1 publication

Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition [ Sci Rep, 2021, 11(1):21689] PubMed: 34737376

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.